1.

Record Nr.

UNINA9910253860803321

Titolo

Human iPS Cells in Disease Modelling / / edited by Keiichi Fukuda

Pubbl/distr/stampa

Tokyo : , : Springer Japan : , : Imprint : Springer, , 2016

ISBN

4-431-55966-3

Edizione

[1st ed. 2016.]

Descrizione fisica

1 online resource (102 p.)

Disciplina

570

Soggetti

Stem cells

Cell culture

Stem Cells

Cell Culture

Lingua di pubblicazione

Inglese

Formato

Materiale a stampa

Livello bibliografico

Monografia

Note generali

Description based upon print version of record.

Nota di bibliografia

Includes bibliographical references at the end of each chapters.

Nota di contenuto

Chapter 1 Recent Improvements and Emerging Issues in iPSC Generation for the Modeling of Disease -- Chapter 2 Cardiomyopathy -- Chapter 3 Modelling Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy with Patient-specific iPSCs -- Chapter 4 Cardiac Arrhythmia Modelling Using iPS Cells -- Chapter 5 iPSC Disease Modeling of Laminopathies -- Chapter 6 Hematological Disorders -- Chapter 7 Inherited Metabolic Disorders of the Liver. .

Sommario/riassunto

Human iPS cells have a great potential to be cell sources for regenerative medicine because of the promise of infinite self-renewal and the capability to differentiate into multiple cell types. This book focuses on another great potential of human iPS cells, which is the establishment of human disease models using patient-specific iPS cells. Human iPS cells can be easily obtained from a patient’s somatic cells and provide the entire information on the patient’s genome. Accordingly, we can generate disease models for inheritable diseases in cell culture dishes using iPS cells. This is a quite new technique but holds tremendous potential for our increased understanding of pathogenesis, and will then be the basis for novel drug development industries. All the authors are leading researchers in this field and they have reported many kinds of patient-derived iPS cells. In this book, they introduce the aspects that could be recapitulated in terms of



disease modelling as well as further innovative findings such as novel pathogenetic insights and novel therapies. .